INAB earnings: real EPS beat/miss history, analyst consensus Buy, P/E -0.33. Updated 2026-07-23.
IN8bio (INAB) Research Hub
IN8bio (INAB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.07 USD (-0.93%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.33, market cap 0.01B. This hub links to the full technical, earnings and options research available for INAB.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.07 USD (-0.93%) |
| 52-week range | 0.9 USD – 1.53 USD |
| Trend regime | Range |
| 14-day RSI | 54.4 (Neutral) |
| Trailing P/E | -0.33 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
Available research for INAB
Covered Call on INAB: how it works, illustrative setup around the real 1.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on INAB: how it works, illustrative setup around the real 1.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on INAB: how it works, illustrative setup around the real 1.07 USD price, max profit/loss, breakeven and when to use it. Educational.
INAB technical analysis: range, last 1.07 USD, RSI 54.4, 52w range 0.9 USD–1.53 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is INAB in?
IN8bio (INAB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is INAB in an uptrend or downtrend?
As of 2026-09-11, INAB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is INAB's trailing P/E ratio?
INAB's trailing P/E is -0.33, with a market cap of 0.01B. See the earnings research page for full valuation detail.